Hypertension and the kidney

[en] The kidney could be the cause of essential hypertension which can also cause renal disease. High blood pressure is also very common in chronic kidney disease, and is moreover a well-known risk factor for a faster progression of kidney failure. Hypertension and kidneys are thus closely linked. Hypertension must be aggressively treated in patients suffering from chronic kidney disease, with a blood pressure goal of less than 130/80 mmHg, even lower than 125/75 mmHg when proteinuria is over 1g/day, using optimal and effective antihypertensive drugs. Among them, the blockers of the renin-angiotensin axis offer nephroprotective but also cardioprotective properties beyond their effect on blood pressure.

Disciplines :

Urology & nephrology

Author, co-author :

Krzesinski, Jean-Marie ; Université de Liège - ULiège > Néphrologie

Cohen, Eric P.; Medical college of Wisconsin, Milwaukee, Wisconsin - USA > Division of Nephrology/Transplantation

Language :

English

Title :

Hypertension and the kidney

Publication date :

2006

Journal title :

Acta Clinica Belgica

ISSN :

0001-5512

Publisher :

Acta Clinica Belgica, Gent, Belgium

Volume :

Issue :

1, Jan-Feb

Pages :

5-14

Peer reviewed :

Peer Reviewed verified by ORBi

Commentary :

www.actaclinicabelgica.be

Available on ORBi :

since 04 February 2009

Statistics

Number of views

86 (4 by ULiège)

Number of downloads

4 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Perera GA. Hypertensive vascular disease: description and natural history. J Chron Dis 1955; 1: 33-42.
Buckalew V, Berg R, Wang S-R et al. Prevalence of hypertension in 1,795 subjects with chronic renal disease: The modification of diet in renal disease study baseline cohort. Am J Kidney Dis 1996; 28: 811-21.
Siewert-Delle, Ljungman S, Andersson O and Wilhelmsen L. Does treated primary hypertension lead to end-stage renal disease? A 20-year follow-up of the primary prevention study by Goteborg, [Sweden]. Nephrol Dial Transplant 1998; 13: 3084-90.
Freis E, Arias L, Armstrong M. et al. Effects of treatment on morbidity in hypertension. JAMA 1967; 202: 1028-34.
Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mmHg. JAMA 1970; 213: 1143-52.
Klag M, Whelton P, Randall B. et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996; 334: 13-8.
Klag M, Whelton P, Randall B. et al. End-stage renal disease in african-american and white men. 16-year MRFIT findings. JAMA 1997; 277: 1293-6.
Hsu C-Y, McCulloch C, Darbinian J, Go A, Iribarren C. Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease. Arch Intern Med 2005; 165: 923-8.
National Kidney Fundation.K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease. Am J Kidney Dis 2004; 43 (suppl 1): S92-S100.
Andersen M, Khawandi W, Agarwal R. Home blood pressure monitoring in CKD. Am J Kidney Dis 2005; 45: 994-1001.
Fukuda M, Munemura M, Usami T. et al. Nocturnal blood pressure is elevated with natriuresis and proteinuria as renal function deteriorates in nephropathy. Kidney Int 2004; 65: 621-5.
Hermida R, Ayala D, Calvo C. et al. Effects of time of day of treatment on ambulatory blood pressure pattern of patients with resistant hypertension. Hypertension 2005; 46 (part 2): 1053-9.
Guyton A, Coleman T, Cowley A et al. Arterial pressure regulation: overriding dominance of the kidneys in long-term regulation in hypertension. Am J Med 1972; 52: 584-94.
Rettig R and Grisk O. The kidney as a determinant of genetic hypertension. Evidence from renal transplantation studies. Hypertension 2005; 46: 463-8.
Curtis J, Luke R, Dustan H. et al. Remission of essential hypertension after renal transplantation. N Engl J Med 1983; 309: 1009-15.
Krzesinski J-M, Warking X, Goffard A et Rorive G. Anomalie rénale de l'excrétion sodée, un marqueur de la prédisposition héréditaire à l'hypertension artérielle. Arch Mal Cœur 1989; 82: 1245-8.
Krzesinski J-M, Saint-Remy A, Du F and Rorive G. Red blood cell Na-Li countertransport, hypertensive heredity, and cardiovascular risk in young adults. Am J Hypertens 1993; 6: 314-6.
Brenner B, Garcia D, Anderson S. Glomeruli and blood pressure. Less of one, more the other? Am J Hypertens 1988; 1: 335-47.
Keller G, Zimmer G, Mall G, Ritz E and Amann K. Nephron number in patients with primary hypertension. N Engl J Med 2003; 348: 101-8.
Freedman B, Iskandar S and Appel R. The link between hypertension and nephrosclerosis. Am J Kidney Dis 1995; 25:207-21.
Zucchelli P and Zuccala A. Primary hypertension - How does it cause renal failure? Nephrol Dial Transplant 1994; 9: 223-5.
Nakagawa T, Kang D-H, Feig D et al. Unearthing uric acid: an ancient factor with recently found significance in renal and cardiovascular disease. Kidney Int 2006; 69: 1722-5.
Hill GS, Heudes D, Jacquot C, Gauthier É and Bariéty J. Morphometric evidence for impairment of renal autoregulation in advanced essential hypertension. Kidney Int 2006; 69: 823-31.
Ruilope L, Campo C and Rodicio J. Relationship between blood pressure and renal function. J Hypertens 1994, 12 (suppl 8): S55-S9.
Campese VM, Mitra N and Sandee D. Hypertension in renal parenchymal disease: Why is it so resistant to treatment? Kidney Int 2006; 69: 967-73.
Brown M and Whitworth J. Hypertension in human renal disease. J Hypertens 1992; 10: 701-2.
Cianciaruso B, Bellizzi V, Minutolo R. et al. Renal adaptation to dietary sodium restriction in moderate renal failure resulting from chronic glomerular disease. J Am Soc Nephrol 1996; 7: 306-13.
Krzesinski J-M, Rorive G. Influence of sodium balance on uremic red blood cell ion transport. Nephron 1988; 49: 126-31.
Bakris G, Williams M, Dworkin L. et al. Preserving renal function in adults with hypertension and diabetes: A consensus approach. Am J Kidney Dis 2000; 36: 646-61.
Brazy P and Fitzwilliam F. Progressive renal disease: Role of race and antihypertensive medications. Kidney Int 1990; 37: 1113-9.
Oldrizzi L, Bright C, De Biase V, Maschio G. The place of hypertension among the risk factors for renal function in chronic renal failure. Am J Kidney Dis 1993; 21 (suppl 2): 119-23.
Peterson J, Adler S, Burkart M et al. Blood pressure control, proteinuria, and the progression of renal disease. Ann Int Med 1995; 123: 754-62.
Ruggenenti P, Perna A and Remuzzi G., on behalf of the investigators of the GISEN Group. Retarding progression of chronic renal disease: The neglected issue of residual proteinuria. Kidney Int 2003; 63: 2254-61.
Shulman N, Ford C, Hall D et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Hypertension 1989; 13 (suppl 1): I-80-I-93.
de Leeuw P, Ruilope L, Palmer C et al. Clinical significance of renal function in hypertensive patients at high risk. Arch Intern Med 2004; 164: 2459-64.
The ALLHAT officers and coordinators for the ALLHAT collaborative research group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-97.
Dalhöf B, Sever P, Poulter N. et al., for the ASCOT investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906.
Wright J, Bakris G, Greene T. et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288: 2421-31.
Agodoa L, Appel L, Bakris G. et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis. A randomized controlled trial. JAMA 2001; 285: 2719-28.
Sarnak M, Greene T, Wang X. et al. The effect of a lower target blood pressure on the progression of kidney disease: Long-term follow-up of the modification of diet in renal disease study. Ann Intern Med 2005; 142: 342-51.
Ruggenenti P, Perna A, Ganeva L. et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet 2005; 365: 939-46.
Ruggenenti P, Perna A, Gherardi G. et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999; 354: 359-64.
Maschio G, Alberti D, Janin G. et al. Effect of the angiotensin- converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996; 334: 939-45.
Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003; 361: 114-24.
Zucchelli P, Zuccalà A, Borghi M. et al. Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int 1992; 42: 452-8.
Jafar T, Stark P, Schmid H. et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition. Ann Intern Med 2003; 139: 244-52.
Sanders P. Salt intake, endothelial cell signaling, and progression of kidney disease. Hypertension 2004; 43: 142-6.
Orth S, Ogata H and Ritz E. Smoking and the kidney. Nephrol Dial Transplant 2000; 15: 1509-11.
Baggio B, Budakovic A, Perissinotto E. et al. Atherosclerosis risk factors and renal function in the elderly: the role of hyperfibrinogenaemia and smoking. Results from the Italian Longitudinal Study on Ageing (ILSA). Nephrol Dial Transplant 2005; 20: 114-23.
Peralta C, Hicks L, Chertow G. et al. Control of hypertension in adults with chronic kidney disease in the United States. Hypertension 2005; 45: 1119-24.
The Guidelines Committee. 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-58.
Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Int Med 2001, 134: 629-36.
National Kidney Fundation.K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease. Am J Kidney Dis 2004; 43 (suppl 1): S16-S41.
Verma S and Strauss M Angiotensin receptor blockers and myocardial infarction. British Medical J 2004; 329: 1248-9.
Derwa A, Peeters P, Vanholder R. Calcium channel blockers in the prevention of end stage renal disease: a review. Acta Clinica Belgica 2004; 59: 44-56.
Gashti C and Bakris G. The role of calcium antagonists in chronic kidney disease. Curr Opinion Nephrol Hypertens 2004; 13: 155-61.
Bakris G, Weir M, Secic M, Campbell B and McNulty W. Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int 2004;65:1991-2002.
MacKinnon M, Shurraw S, Akbari A. et al. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: A systematic review of the efficacy and safety data. Am J Kidney Dis 2006; 48: 8-20.
Aperloo A, de Zeeuw D and De Jong P. A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function. Kidney Int 1997; 51: 793-7.